Dyne Therapeutics' (DYN) "Buy" Rating Reiterated at Chardan Capital

Dyne Therapeutics (NASDAQ:DYN - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at Chardan Capital in a research note issued to investors on Friday,Benzinga reports. They presently have a $50.00 price objective on the stock. Chardan Capital's price target indicates a potential upside of 330.66% from the stock's current price.

Several other research analysts have also recently issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $46.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 17th. Royal Bank of Canada reissued an "outperform" rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Scotiabank assumed coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price objective for the company. Guggenheim restated a "buy" rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Finally, Piper Sandler cut their target price on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $46.85.

Dyne Therapeutics Trading Down 4.0%

Dyne Therapeutics stock traded down $0.49 during midday trading on Friday, reaching $11.61. 1,364,121 shares of the stock traded hands, compared to its average volume of 1,667,020. The company has a 50-day simple moving average of $10.37 and a two-hundred day simple moving average of $17.81. The firm has a market cap of $1.32 billion, a PE ratio of -3.26 and a beta of 1.19. Dyne Therapeutics has a 12-month low of $6.36 and a 12-month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). Equities research analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Insider Activity

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. This represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 6,237 shares of company stock valued at $77,760 over the last ninety days. 14.14% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Dyne Therapeutics by 378.6% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock worth $32,000 after buying an additional 2,446 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Dyne Therapeutics in the 4th quarter valued at approximately $50,000. KBC Group NV lifted its stake in Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company's stock worth $74,000 after purchasing an additional 978 shares in the last quarter. E Fund Management Co. Ltd. grew its stake in Dyne Therapeutics by 16.2% in the 1st quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company's stock worth $144,000 after buying an additional 1,923 shares in the last quarter. Finally, AlphaQuest LLC purchased a new position in shares of Dyne Therapeutics in the 1st quarter worth about $171,000. Institutional investors and hedge funds own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.